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RICHARD WORMALD, ASTRID E. FLETCHER, DEREK G. COOK, AND CHRISTOPHER G. OWEN PURPOSE: To estimate incidence of age-related macular
degeneration (AMD) by subtype in American whites aged
‡50 years.
 DESIGN: Systematic review and meta-analysis.
 METHODS: SETTING: Prospective cohort studies of
AMD incidence in populations of white European
ancestry published in MEDLINE, EMBASE, and Web
of Science. STUDY POPULATION: Fourteen publications in
10 populations that examined AMD incident cases were
identified. OBSERVATION PROCEDURE: Data on age-sex-
specific incidence of late AMD, geographic atrophy
(GA) and neovascular AMD (NVAMD), year of recruit-
ment, AMD grading method, and continent were
extracted. MAIN OUTCOME MEASURE(S): Annual incidence
of late AMD, GA, and NVAMD by age-sex in American
whites aged ‡50 years from a Bayesian meta-analysis of
incidence studies was compared with incidence extrapo-
lated from published prevalence estimates.
 RESULTS: Incidence rates from the review agreed with
those derived from prevalence, but the latter were based
onmore data, especially at older ages and byAMDsubtypes.
Annual incidence (estimated fromprevalence) of lateAMD
inAmerican whites was 3.5 per 1000 aged ‡50 years (95%
credible interval 2.5, 4.7 per 1000), equivalent to 293 000
new cases inAmericanwhites per year (95% credible inter-
val 207 000, 400 000). Incidence rates approximately
quadrupled per decade in age. Annual incidence GA rates
were 1.9 per 1000 aged ‡50 years, NVAMD rates were
1.8 per 1000. Late AMD incidence was 38% higher in
women vs men (95% credible interval 6%, 82%).
 CONCLUSIONS: Estimating AMD incidence from
prevalence allows better characterization at older ages
and by AMD subtype where longitudinal data from
incidence studies are limited. (Am J Ophthalmol
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E
STIMATING THE NUMBER IN A POPULATION WITH
late age-related macular degeneration (AMD) is
important for estimating health service need and pro-
vision, especially in the context of providing new treat-
ments.1 While prevalence measures the proportion with
disease in the population, incidence is a key measure to
examine new cases over time, allowing current demand for
health services to be planned. Additionally, monitoring
changes in incidence over time may relate to changes in po-
tential risk factors, providing clues to etiology and pathways
to prevention. While a large number of population-based
studies have reported the prevalence of AMD in older peo-
ple,2–4 fewer have reported incidence, especially with long-
term follow-up.5–7 Disability, frailty owing to reduced vision
and/or othermorbidities, andmortality are factors leading to
loss to follow-up and nonparticipation over time. Differ-
ences in duration of follow-up, especially at older ages, will
impact on incidence and may explain variability in esti-
mates of incidence between studies.5,8–10 Low response
rates, especially in the oldest age groups where AMD is
more common, will lead to an underestimation of disease
incidence. Moreover, when generalizing to a population at
large, it is important that demographic characteristics of
the entire population are taken into account. We have
carried out a Bayesian meta-analysis of studies examining
AMDincidence, allowing for differences in age andduration
of follow-up. Incidence can also be estimated from age-
specific prevalence.11 We compare estimates of incidence
from themeta-analysis of incidence studieswith that derived
from a meta-analysis of prevalence estimates4 applied to the
American white population demographics.
METHODS
 SYSTEMATIC REVIEW PROCESS: Eligible studies were
those that reported on the prevalence and/or incidence
of AMD. We searched MEDLINE (1950 onwards),
EMBASE (1960 onwards), and Web of Science (1960 on-
wards) electronic databases; the search was updated to85LISHED BY ELSEVIER INC.
October 2012.4 A combination of text words for AMD
(age-related macula$ degeneration/age related maculop-
athy/senile macula$ degeneration) and epidemiologic
terms (inciden$/prevalen$/Population$/Survey$) were
combined with related subject headings in MEDLINE
and EMBASE only (in addition to MESH/subject headings
for population study designs). Studies that quantified the
incidence of late AMD, geographic atrophy (GA), and/
or neovascular AMD (NVAMD) from a nondiseased state
at baseline (in 1 or both eyes), in population-based samples
of European ancestry, with detailed methods of sampling,
were included. Studies were excluded if they were carried
out in other racial groups, where nonspecific volunteers
or those from particular professions (except for 1 study of
American watermen)12 were included, if they were hospi-
tal audits/surveys, or where self-reported diagnoses were
made or clinical diagnosis was only ascertained in those
with reduced vision (as these may represent a subgroup
with disease). Papers reporting incidence rates based on
counting eyes rather than individuals were also excluded.
In total, 74 studies on incidence and prevalence were found
and reviewed in detail (by A.R.R., Z.J., and C.G.O.), from
which 14 publications based on 10 population studies
contained relevant incidence data.
 DATA EXTRACTION: AMD incidence rates (and associ-
ated 95% confidence limits and/or standard errors) were
extracted, or calculated from the number of new cases re-
ported over time (person-years), by age and sex, if avail-
able. The reported mean (or median) age at baseline or
midpoint of the age range reported was used for analysis.
If the age group was specified as younger than x, older
than x, or xþ, then the age band was taken to be the
same width as other age groups reported in the same study.
The calendar year at baseline, period of follow-up, and
number of participants were also recorded where available.
Whether International Classification System or Wisconsin
Age-Related Maculopathy Grading System (or other sys-
tems) were used was recorded,13,14 as was whether 1 eye
or both eyes were examined (with or without fundus
imaging). The geographic location of the study was
extracted and classified into 3 continental regions
(America, Australasia, Europe). We recorded whether an
individual was defined as a case of AMD on the basis of
disease being present in either eye/worse eye/at least 1
eye/1 or both eyes or only in 1 eye randomly selected for
ocular assessment. Late AMD refers to eyes with GA
and/or NVAMD. Data on other potential confounders,
such as smoking, were not routinely available. Data were
extracted by 3 reviewers (Z.J., A.R.R., C.G.O.) with
independent extraction on a subgroup of studies.
Disagreements were resolved by discussion.
 META-ANALYSIS OF INCIDENCE STUDIES: Most of the
studies reported cumulative incidence as a percentage;
only 1 study reported rates by person-years of follow-up.1586 AMERICAN JOURNAL OFAssuming incidence rates follow a Poisson distribution, a
meta-analysis of incidence rates requires the number of
cases of AMD along with the person-years of follow-up
for each study. For the other studies either the person-
years or the number of cases of AMD had to be derived
from the published estimates of cumulative incidence and
average duration of follow-up. If the number of new cases
of AMD or person-years of follow-up were not reported,
they were estimated from the reported cumulative inci-
dence and average duration of follow-up. An assumption
was made that cases of AMD occurred halfway through
the follow-up period and that non-cases were followed-up
for the entire duration of the study to give an approxima-
tion for person-years of follow-up for each study. Study-
specific incidence rates were combined using Bayesian
Poisson meta-regression, adjusting for age, year of recruit-
ment (to examine trends in incidence over time), conti-
nent (to examine geographic variations in incidence
among populations of the same ancestry), and AMD classi-
fication system, to produce mutually adjusted rate ratios.
Our model took into account that some studies had inci-
dence rates for more than 1 age group and 3 population-
based studies reported incidence rates at different time
points (eg, 5-, 10-, 15-year incidence).5–7,10,15–17 As in
our previous meta-analyses of prevalence,4,18 within-study
repeated measures of incidence were modeled by a Poisson
multilevel Bayesian meta-regression using WinBUGS soft-
ware (MRC Biostatistics Unit, Cambridge, UK). Our
model simultaneously took account of the following study
level confounders: average age, sex, year of survey (to
examine trends in incidence over time), continent (to
examine geographic variations in incidence among popula-
tions of the same ancestry), and AMD classification system,
to produce mutually adjusted rate ratios. ESTIMATING AGE-RELATED MACULAR DEGENERATION
INCIDENCE FROM AGE-RELATED MACULAR DEGENERA-
TION PREVALENCE: We obtained the prevalence of late
AMD, GA, NVAMD (for men, women, and sexes com-
bined) for each year of age from 50 to 97 years (the oldest
reported age in the studies included)4 from our earlier
meta-analysis of 31 prevalence surveys (with 51 173 partic-
ipants, including 1571 cases of late AMD, 455 with GA,
and 404 with NVAMD).4 These prevalence estimates allow
for study characteristics, such as age of the sample, examina-
tion methods, and definitions of disease (internationally
recognized definitions being preferred),13,14 and represent
the most up-to-date meta-analysis of AMD prevalence in
white populations, similar to the older white population of
the US. Age-sex-specific estimates of prevalence standard-
ized to studies using fundus imaging and either International
Classification System or Wisconsin Age-Related Maculop-
athy Grading System were applied to 2011 American white
population estimates19 to give the prevalence of late AMD,
GA, and NVAMD and absolute number of prevalent cases
by 5-year age bands in men and women separately andJULY 2015OPHTHALMOLOGY
TABLE 1. Studies of Age-Related Macular Degeneration Incidence in White Populations
First Author, Year Study Name/Location, Country Age Range (Years) Duration (Years)
Data by Sex AMD Type
Grading System
AMD Assessment
No. Participants Cumulative Incidence (%)M F All Late NV GA FI EE
Bressler, 199512 Waterman Study, USA >_70 5 U U WARM U 50 2.0
Chang, 200821 Salisbury Eye Evaluation (SEE) Project, USA 65–86 2 U U SS U 1156 0.3
Coleman, 201022 Oregon, Minneapolis, Baltimore, and
Pennsylvania, USA
74–85þ 5 U U WARM U 1493 6.2
Delcourt, 200525 Pathologies Oculaires Liees a l’Age Study,
France
65–85þ 3 U U IC U 1424 0.5
Jonasson, 200524 Reykjavik Eye Study, Iceland 50–80þ 5 U U U U IC U 693 1.2
Klaver, 200117 Rotterdam Study, Netherlands 55–85þ 2 U U U U IC U 4953 0.24
van Leeuwen 200315 Rotterdam Study, Netherlands 55–80þ 6.5 U U U U WARM U 3636 1.8a
Klein, 199716 Beaver Dam Eye Study, USA 43–86 5 U U U U WARM U 3502 0.9
Klein, 200210 Beaver Dam Eye Study, USA 43–86 10 U U U U WARM U 3496 2.1
Klein, 20076 Beaver Dam Eye Study, USA 43–86 15 U U U U U U WARM U 3830 3.1
Mitchell, 20025 Blue Mountains Eye Study, Australia <60–80þ 5 U U U U U U WARM U 2312 1.1
Wang, 20077 Blue Mountains Eye Study, Australia <60–80þ 10 U U U U U U WARM U 2395 3.7
Mukesh, 200426 Melbourne Visual Impairment Project,
Australia
40–80þ 5 U U U U IC U U 1618 0.5
Sparrow, 199723 Melton Mowbray, England 84–97 7 U U U U WARM U 82 4.9
AMD¼ age-relatedmacular degeneration; EE¼ eye examination; FI¼ fundus imaging; GA¼ geographic atrophy/dry AMD; IC¼ International Classification System; NV¼ neovascular/exudative/
wet AMD; SS ¼ study specific; WARM ¼ Wisconsin Age-Related Maculopathy Grading System.
aIncidence rate per 1000 person-years.
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combined. We give the 95% credible intervals of preva-
lence, which represents the range of values within which
the true prevalence is expected to lie with 95% probability.
Owing to the relatively small number of longitudinal
studies reporting incidence by AMD subtype and by sex
(especially at older ages), we also derived estimates of inci-
dence from age-sex-specific prevalence (standardized to
studies using fundus imaging and either International Clas-
sification System or Wisconsin Age-Related Maculopathy
Grading System)4 using a method previously reported for
estimating incidence of major causes of eye disease
(including ‘‘senile macular degeneration’’) from the
Framingham Eye Study.11 The method assumes that (1)
the duration of disease is life-long after diagnosis, since
the disease is considered to be irreversible; (2) mortality
risk is the same in diseased and nondiseased individuals;
and (3) disease incidence and population composition (in
terms of risk factors for late AMD) remain stable over
time. These assumptions refer to the population at large,
not the study population. Calculation of incidence requires
knowledge of the population at the beginning of a given
age interval (available from the US Census Bureau19),
the probability of dying (available from the National
Centre for Health Statistics),20 and the probability of
AMD (estimated from prevalence) for the same age inter-
val. We used this approach to estimate the annual inci-
dence per 1000 by age for late AMD, GA, and NVAMD
in men and women separately and combined.
Data presented on prevalence and incidence are based
on ‘‘either eye’’ definitions (including at least 1 eye, worse
eye, 1 or both eyes) using the International Classification
System or Wisconsin Age-Related Maculopathy Grading
System along with fundus imaging.FIGURE 1. Incidence per 1000 person-years of late age-related
macular degeneration (AMD), geographic atrophy (GA), and
neovascular age related macular degeneration (NVAMD) by
age for each population. Square symbols represent the estimated
incidence per 1000 person-years of late AMD (Top), GA (Mid-
dle), and NVAMD (Bottom) at a given age for each study. Data
points from the same study are joined by a straight line. The size
of each symbol is inversely proportional to the standard error of
the estimate of incidence. The vertical axis is plotted on a loga-
rithmic scale.RESULTS
IN TOTAL, 14 PUBLICATIONS WITH DATA ON AMD INCI-
dence in 10 populations were identified (Table 1). Four
of the populations were based in the US,6,10,12,16,21,22 4 in
western Europe,15,17,23–25 and 2 in Australia.5,7,26 For late
AMD this equates to approximately 135 000 person-years
of follow-up with 361 incident cases of AMD. Twelve pub-
lications presented data for late AMD in men and women
combined, and 10 publications provided data by sex.
 SYSTEMATIC REVIEW AND META-ANALYSIS OF INCI-
DENCE STUDIES: The incidence per 1000 person-years of
late AMD, GA, and NVAMD by age for each population
is shown in Figure 1. Incidence is plotted on a logarithmic
scale and shows a linear increase with age. A meta-analysis
of incidence studies showed that the incidence rate for late
AMD triples per decade increase in age (rate ratio 2.9; 95%
credible interval 2.6, 3.2, Table 2). There was no evidence
of a trend in late AMD incidence rates over time. There88 AMERICAN JOURNAL OFwas no evidence of a difference between studies using Inter-
national Classification System or Wisconsin Age-Related
Maculopathy Grading System (Table 2). While late
AMD incidence rates appeared marginally higher in the
US and Australia, compared to Europe (Table 2), there
were only a small number of studies and credible intervalsJULY 2015OPHTHALMOLOGY
TABLE 2. Mutually Adjusted Rate Ratios for Late
Age-Related Macular Degeneration From Bayesian
Meta-regression Model
Factor
No. of Study
Populations
Adjusted Rate
Ratioa (95% Cri)
Per decade increase in age 8 2.91 (2.63, 3.23)
Per calendar year 8 1.07 (0.99, 1.17)
Europe 4 1.00
United States 2 1.62 (0.73, 3.44)
Australia 2 1.72 (0.73, 3.01)
AMD grading system
WARM 3 1.00
IC 5 0.76 (0.38, 1.40)
Women vs menb 7 1.38 (1.06, 1.82)
95% Cri ¼ Bayesian 95% credible interval; IC ¼ International
Classification System; WARM ¼Wisconsin Age-Related Macul-
opathy Grading System.
aRate ratios from analysis based on 8 population studies
(sexes combined) adjusted for all factors listed in table except
sex.
bThe comparison of women vs men is from a separate meta-
analysis in the subset of 7 studies that reported data stratified
by sex, taking account of the other factors listed in the table.
FIGURE 2. Annual incidence per 1000 of late age-related mac-
ular degeneration against age from a meta-analysis of incidence
studies in populations of white European ancestry (solid circles)
and as estimated from age-specific prevalence (open squares)
applied to the demographics of the American white population.
Incidence on the vertical axis is on a logarithmic scale.were wide (and included the null value of 1). Hence, there
was no strong evidence of geographic differences in late
AMD incidence. However, while the same incident rates
may apply, the age-sex structure of populations in these
countries are heterogeneous; hence, the number of inci-
dent cases will differ markedly between countries. Inci-
dence rates for late AMD were 38% higher in women
than in men (rate ratio 1.4, 95% credible interval 1.1,
1.8). Exclusion of 1 small study carried out on American
watermen, at the margins of the inclusion criteria, made
no difference to the point estimate and marginally widened
the confidence interval (odds ratio 1.38, 95% credible in-
terval 1.08, 1.83). Incidence data for GA or NVAMD sepa-
rately were available for 4 populations only. These data
were insufficient to provide stable estimates of incidence
by year of age by AMD subtypes.
 INCIDENCEOFAGE-RELATEDMACULARDEGENERATION
IN THE AMERICAN WHITE POPULATION: Applying age-
specific prevalence estimates from a recent meta-analysis4
to the American white population aged 50–97 years gave
an overall prevalence of late AMD of 2.3% (95% credible
interval 1.7%, 3.2%). The Supplemental Table (available
at AJO.com) gives estimates by age, sex, and AMD subtype.
Figure 2 shows the 2 methods used to estimate annual inci-
dence rate; A from the Bayesian meta-regression of inci-
dence studies in populations of white European ancestry
and B incidence estimated by applying age-specific preva-
lence4 to the population demographics of the American
white population. The 2 approaches yield similar rates (seeVOL. 160, NO. 1 AMERICAN WHITE INCIDENCE OF AGE-Rabsolute rate differences given in Figure 2), with a steeper
rise with age with method B (approximately quadrupling
per decade; rate ratio 3.9, 95% credible interval 3.8, 4.0).
Incidence estimated from age-specific prevalence yielded a
tighter 95% credible interval and we were able to estimate
it over a wider age range, as well as by AMD subtype and
sex. Overall annual incidence inAmerican whites estimated
from prevalence is 3.5 per 1000 (95% credible interval 2.5,
4.7) for late AMD in those aged 50–97 years. The corre-
sponding rates for GA and NVAMD are 1.9 per 1000
(95% credible interval 1.3, 2.8) and 1.8 per 1000 (95% cred-
ible interval 1.2, 2.5), respectively (Table 3). This corre-
sponds to approximately 293 000 new cases of late AMD
each year (95% credible interval 207 000, 400 000), and
160 000 (95% credible interval 107 000, 234 000) and
148 000 (95% credible interval 103 000, 207 000) for GA
and NVAMD, respectively. The estimated total number of
new cases rises rapidly from age 50 years to the mid-80s
and then begins to drop (Figure 3). In those aged 65 years
and older the annual incidence rate for late AMD is 7.8
per 1000 (95% credible interval 5.5, 10.6), 4.3 per 1000
for GA (95% credible interval 2.9, 6.2), and 3.9 per 1000
for NVAMD (95% credible interval 2.7, 5.5). In those
aged 80 years and older the annual incidence rates per
1000 are 19.4 (95% credible interval 13.8, 26.2), 10.9
(95% credible interval 7.2, 16.1), and 9.9 (95% credible in-
terval 6.8, 14.0), respectively. Under 70 years of age the
number of incident cases is similar in men and women.
Beyond 70 years of age the number of new cases of AMD
is consistently higher in women than in men (Table 3,
Figure 3). For all age groups (except the youngest), women
have a slightly higher annual incidence rate of late AMD
(4 per 1000, 95% credible interval 2.3, 6.6) than men (2.4
per 1000, 95% credible interval 1.4, 4.2; Table 3). Overall,
women have a marginally higher rate of GA than men,89ELATED MACULAR DEGENERATION
TABLE 3. Estimated Number of New Cases Each Year and Average Annual Incidence per 1000 of Age-Related Macular Degeneration
(Late Age-Related Macular Degeneration, Geographic Atrophy, Neovascular Age-Related Macular Degeneration) by 5-Year Age
Groups for Men and Women in the White American Population
Age Group (Years)
Number of New Cases per Year in 1000s (95% Cri) Estimated Annual Incidence per 1000 (95% Cri)
Late AMD GA NVAMD Late AMD GA NVAMD
Men
50–54 1.4 (0.8, 2.6) 0.9 (0.5, 1.6) 0.8 (0.5, 1.5) 0.2 (0.1, 0.3) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2)
55–59 2.5 (1.4, 4.6) 1.6 (1.0, 2.7) 1.4 (0.8, 2.5) 0.3 (0.2, 0.6) 0.2 (0.1, 0.3) 0.2 (0.1, 0.3)
60–64 4.4 (2.4, 8.0) 2.8 (1.7, 4.6) 2.5 (1.5, 4.2) 0.6 (0.3, 1.1) 0.4 (0.2, 0.7) 0.4 (0.2, 0.6)
65–69 6.4 (3.5, 11.5) 4.1 (2.6, 6.5) 3.5 (2.1, 5.8) 1.3 (0.7, 2.3) 0.8 (0.5, 1.3) 0.7 (0.4, 1.1)
70–74 9.0 (5.1, 16.4) 5.8 (3.7, 9.2) 4.8 (2.9, 8.2) 2.5 (1.4, 4.5) 1.6 (1.0, 2.5) 1.3 (0.8, 2.3)
75–79 13.3 (7.5, 23.7) 8.6 (5.4, 13.8) 6.9 (4.1, 12.0) 4.9 (2.8, 8.8) 3.2 (2.0, 5.1) 2.6 (1.5, 4.4)
80–84 18.8 (10.7, 32.7) 12.3 (7.6, 20.1) 9.7 (5.7, 17.0) 9.5 (5.4, 16.6) 6.2 (3.9, 10.2) 4.9 (2.9, 8.6)
85–89 20.5 (11.8, 34.6) 13.7 (8.2, 22.6) 10.6 (6.2, 18.7) 17.7 (10.2, 29.8) 11.8 (7.1, 19.5) 9.1 (5.3, 16.1)
90þ 19.5 (11.9, 30.1) 13.6 (8.0, 22.4) 10.5 (6.1, 18.3) 33.4 (20.3, 51.5) 23.3 (13.7, 38.3) 18.0 (10.4, 31.4)
All ages 95.8 (55.1, 164.2) 63.3 (38.7, 103.5) 50.7 (29.8, 88.0) 2.4 (1.4, 4.2) 1.6 (1.0, 2.6) 1.3 (0.8, 2.2)
Women
50–54 1.6 (0.9, 3.0) 0.9 (0.5, 1.6) 1.0 (0.6, 1.8) 0.2 (0.1, 0.3) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2)
55–59 3.0 (1.6, 5.4) 1.7 (1.0, 2.8) 1.8 (1.1, 3.2) 0.4 (0.2, 0.6) 0.2 (0.1, 0.3) 0.2 (0.1, 0.4)
60–64 5.3 (2.9, 9.8) 3.0 (1.8, 4.9) 3.3 (1.9, 5.5) 0.7 (0.4, 1.3) 0.4 (0.2, 0.7) 0.4 (0.3, 0.7)
65–69 8.0 (4.5, 14.6) 4.5 (2.9, 7.3) 4.8 (2.9, 8.0) 1.4 (0.8, 2.6) 0.8 (0.5, 1.3) 0.8 (0.5, 1.4)
70–74 12.2 (6.8, 21.9) 6.9 (4.4, 10.9) 7.0 (4.3, 12.0) 2.8 (1.6, 5.1) 1.6 (1.0, 2.5) 1.6 (1.0, 2.8)
75–79 19.7 (11.2, 35.0) 11.2 (7.1, 17.9) 11.2 (6.8, 19.2) 5.6 (3.2, 9.9) 3.2 (2.0, 5.1) 3.2 (1.9, 5.4)
80–84 32.6 (18.5, 55.7) 18.7 (11.7, 30.5) 18.2 (10.9, 31.5) 10.8 (6.1, 18.5) 6.2 (3.9, 10.1) 6.0 (3.6, 10.5)
85–89 43.5 (25.3, 71.7) 25.8 (15.8, 42.6) 24.5 (14.5, 42.3) 19.9 (11.6, 32.8) 11.8 (7.2, 19.5) 11.2 (6.6, 19.3)
90þ 53.5 (33.2, 80.9) 34.1 (20.7, 55.3) 31.7 (18.9, 53.5) 37.4 (23.2, 56.5) 23.8 (14.5, 38.6) 22.2 (13.2, 37.3)
All ages 179 (105, 298) 107 (66.0, 174) 104 (61.9, 177) 4.0 (2.3, 6.6) 2.4 (1.5, 3.8) 2.3 (1.4, 3.9)
Men and women
50–54 3.0 (2.0, 4.3) 1.5 (0.9, 2.4) 1.6 (1.0, 2.3) 0.2 (0.1, 0.2) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1)
55–59 5.5 (3.8, 7.9) 2.8 (1.8, 4.2) 2.8 (1.9, 4.0) 0.3 (0.2, 0.5) 0.2 (0.1, 0.3) 0.2 (0.1, 0.2)
60–64 10.1 (6.9, 14.1) 5.1 (3.4, 7.3) 5.1 (3.5, 7.0) 0.7 (0.5, 1.0) 0.3 (0.2, 0.5) 0.3 (0.2, 0.5)
65–69 15.1 (10.5, 21.2) 7.7 (5.2, 10.8) 7.5 (5.3, 10.1) 1.4 (1.0, 2.0) 0.7 (0.5, 1.0) 0.7 (0.5, 0.9)
70–74 22.7 (15.8, 31.6) 11.6 (8.1, 16.4) 11.1 (8.0, 14.9) 2.9 (2.0, 4.0) 1.5 (1.0, 2.1) 1.4 (1.0, 1.9)
75–79 35.8 (24.9, 49.7) 18.5 (12.8, 26.4) 17.4 (12.4, 23.7) 5.7 (4.0, 8.0) 3.0 (2.1, 4.2) 2.8 (2.0, 3.8)
80–84 56.2 (39.3, 77.8) 29.7 (20.1, 43.2) 27.5 (19.4, 38.0) 11.3 (7.9, 15.6) 6.0 (4.0, 8.7) 5.5 (3.9, 7.6)
85–89 70.4 (49.6, 95.7) 38.7 (25.8, 57.3) 35.2 (24.3, 50.1) 21.0 (14.8, 28.6) 11.6 (7.7, 17.1) 10.5 (7.3, 15.0)
90þ 74.1 (54.2, 97.5) 44.3 (28.8, 65.9) 39.9 (26.9, 57.0) 36.7 (26.9, 48.4) 22.0 (14.3, 32.7) 19.8 (13.4, 28.3)
All ages 293 (207, 400) 160 (107, 234) 148 (103, 207) 3.5 (2.5, 4.7) 1.9 (1.3, 2.8) 1.8 (1.2, 2.5)
95% Cri ¼ Bayesian 95% credible interval; AMD ¼ age-related macular degeneration; GA ¼ geographic atrophy/dry AMD; NV ¼
neovascular/exudative/wet AMD.
Incidence estimated from prevalence for men and women combined is based on a meta-analysis of 30 prevalence studies, whereas esti-
mates stratified by sex are from a meta-analysis of 19 studies that reported AMD prevalence by sex.
Absolute number of new cases per year is calculated by multiplying the numbers in the second, third, or fourth column by 1000, (eg, total
number of cases of late AMD across all ages in men and women combined is 293 3 1000 ¼ 293 000).but within each 5-year age group incidence rates in Table 3
for GA appear similar in men and women and this is partly
owing to rounding. In those aged 65 years and older the inci-
dence rates of NVAMD within each 5-year age group are
higher in women than in men.
We carried out sensitivity analyses to test the assumption
of equal mortality in cases and non-cases of AMD in esti-
mating incidence from prevalence. If we assume substantial
differences in mortality of up to 20% higher or 20% lower
in cases of AMD, the incidence estimates are contained
within the 95% credible intervals presented in Table 3.90 AMERICAN JOURNAL OFThe Supplemental Figure (available at AJO.com) shows
the effect of differences in mortality 5%, 10%, and 20%
higher or lower on the age-sex-specific incidence rates. It
is noteworthy that a 20% higher or lower mortality is sub-
stantial, and the estimated age-sex annual incidence is
contained within the original 95% credible intervals.
If we restrict our previous meta-analysis of prevalence4 to
US studies only (13 prevalence studies), the point esti-
mates are included within the 95% credible interval
presented in tables based on all studies of white European
ancestry (30 prevalence studies that included both menJULY 2015OPHTHALMOLOGY
FIGURE 3. Graphs showing the annual incidence (estimated
from age-specific prevalence) as the number of new cases per
year in the American white population of late age-related macu-
lar degeneration (Top), geographic atrophy (Middle), and
neovascular age-related macular degeneration (Bottom). Men
are illustrated by open squares and women by solid circles.and women); that is, estimates are in line with those
already presented for all whites of European ancestry. How-
ever, the 95% credible intervals are much wider (ie, less
precise) when the meta-analysis is restricted to US-only
studies. This is what we would expect. Restricting the
meta-analysis to US studies reduces the power, as the
number of participants and cases of AMD contributing
to the analysis is reduced.VOL. 160, NO. 1 AMERICAN WHITE INCIDENCE OF AGE-RDISCUSSION
WE PROVIDE THE MOST UP-TO-DATE ESTIMATES OF THE
number of new cases of late AMD among American whites
per year. We show an exponential rise in AMD incidence
with age and that women have a higher annual incidence
rate of late AMD compared to men. Although late AMD
incidence increases log-linearly with age, the absolute
number of incident cases of late AMD decreases beyond
the age of about 85 years because of increased mortality.
Owing to the limited number of prospective studies that
report incidence by age, sex, and AMD subtype, we chose
to estimate incidence from age-specific prevalence. However,
a key question is whether this is comparable to obtaining inci-
dence rates directly from a meta-analysis of prospective
studies. Unfortunately, incidence rates were not systemati-
cally reported in prospective studies and had to be estimated
from cumulative incidence and average duration of follow-up
(except for 1 study17). Approximating person-years of follow-
up for each study fromaggregated data (rather than individual
data) may make rate estimates less accurate, especially with a
disease that increases exponentially with age, in a population
with high rates of other morbidities and mortality. In addi-
tion, follow-up in elderly prospective studies is challenging.
There are a greater number of prevalence surveys that
included data at older ages, allowing AMD incidence to be
estimated over a wider age range by AMD subtype as well as
in men and women separately. However, deriving incidence
from prevalence requires a number of assumptions about the
population: first, that disease remains incurable; second,
that those with disease have similar mortality rates to those
without; and third, that risk factors for disease remain stable.
In terms of late AMD these assumptions are appropriate, as
the first is correct, there is currently no evidence to argue
against the second,27–29 and while risk factors may have
altered over time, particularly with reductions in cigarette
smoking and improved diets,30,31 occurrence of the disease
appears to have remained stable among studies with
preferred methodologies (ie, using fundus imaging and
international classification of disease)4,13,14 and our meta-
analysis did not elicit any trends in AMD incidence over
time (Table 2). Similarly, our meta-analysis of prevalence
studies over an extended period of 30 years4 did not show ev-
idence of any trends in late AMD prevalence over time. This
is consistent with recent evidence from serial data from the
National Health and Nutrition Examination Survey
(USA), which suggests that apparent declines in ‘‘any’’
AMD might be explained in part by methodological
differences between successive surveys.32 Figure 2 shows com-
parable estimates of incidence obtained directly from a
meta-analysis of incidence studies and those estimated from
age-specific prevalence obtained fromameta-analysis of prev-
alence estimates4 standardized to the American white
population demographics. Findings are further supported by
our sensitivity analysis, presented as a Supplemental Figure,91ELATED MACULAR DEGENERATION
illustrating that there would have to be stark differences in
mortality between cases and non-cases of AMD to substan-
tially alter incidence estimated from prevalence.
In proportionate terms, annual incidence rates from prev-
alent studies suggest a quadrupling in risk per decade,
whereas the meta-analysis of incidence studies suggests a
tripling. Shortage of data at older ages and selection effects
associated with longer-term follow-up may explain the
weaker increase in incidence with age among incidence
studies, compared to estimates from prevalence. Previous re-
ports from prospective studies have also found a proportion-
ate rise in AMD incidence with age but with less certainty,
as these are often reported by broad age groups6,9,17,26 and
are heavily dependent on the distribution of age within
each study and duration of follow-up.
An individual participant meta-analysis could provide
more accurate data on follow-up and exact age at event and
adjust for individual environmental or genetic factors. Such
an approach is preferable if these data can be obtained for
all relevant studies.However, the difficultywith an individual
patient datameta-analysis is that it is likely to represent a sub-
set of well-resourced studies and may be biased if it is not
representative of all studies. By adopting a more inclusive
approach, we were able to include more studies, representing
a wider age range of participants and increased sample size;
this allowed more precise estimates of incidence for each
year of age. We took account of study-level confounders
including continent, AMD grading system, age, and sex and
examined trends over time.We showed that there is no clear
evidence of differences in late AMD incidence across the 3
continents. If we restrict themeta-analysis to studies conduct-
ed in the US alone the point estimates are contained within
the 95% credible interval already presented in the paper.
However, 95% credible interval based on studies conducted
in the US only are less precise, with wider credible intervals,
because they are based on fewer studies.
The higher incidence of late AMD observed in women,
particularly for NVAMD, is supported by data published
from prospective studies.5–7,9,10,16,26 However, data from
individual studies are often insufficiently powered to find a92 AMERICAN JOURNAL OFstatistically significant difference between men and
women. By applying our age-specific prevalence rate esti-
mates to the US population we have been able to demon-
strate and quantify the sex difference in AMD incidence
rates and by AMD subtype. While these sex differences
may have hormonal/menopausal etiologies,33 there is
increasing interest in whether this might be linked to sex dif-
ference in cerebrovascular events,34 especially for NVAMD,
where women have higher rates at older ages35 (as cerebro-
vascular mortality may have already occurred in men).
Although our overall estimates of NVAMD incidence are
high (owing to the inclusion of those at older ages, especially
in women), this does not reflect the number in need of treat-
ment. The type of NVAMD on presentation cannot be esti-
mated from these data, although some evidence suggests two
thirds are likely to have classic forms of the disease that may
benefit from treatment.36 Of note, the inclusion of older ages
in our estimates may include a large number who are unwill-
ing or too frail to undergo treatment.
Findings from this study provide clear recommendations
for the use and interpretation of study methods, particularly
the ascertainment of AMD cases in the future. The review
provides contemporary estimates of the number of incident
cases of late AMD, GA, and NVAMD in the white older
population of the US. Accurate prediction of the numbers
of new cases of late AMD, by type, is needed in order to
more accurately estimate the cost of AMD, which will
inform current and future healthcare provision. It is impor-
tant to give country-specific data, when the potential
impact on clinical practice and social service provision is
very country dependent. Approximately 89% of the US
population aged 80 years and older is white.19 Evidence
suggests similar or lower rates of AMD in populations of
non-European ancestry, but data are sparse.2,37 These
data demonstrate that late AMD is a significant public
health problem, especially in an aging population.
Although not all new cases of AMD would be eligible for
treatment, they may require visual rehabilitation. As new
therapies become available, the proportion of new cases
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SUPPLEMENTAL FIGURE. The influence of differential mortality for individuals with late age-related macular degeneration
(AMD) compared to those not affected by late AMD on the age-specific annual incidence of late AMD estimated from age-specific
prevalence. The solid black round symbols are the point estimates already presented in the article, assuming that those with late
AMD have the same mortality as those without late AMD. The corresponding 95% credible intervals are shown as solid black lines.
The dashed lines assume that those with late AMD have a higher mortality and the dashed-dot lines assume that those with late AMD
have a lower mortality. The line color corresponds to a difference in mortality of 5% for cyan, 10% for blue, and 20% for the red lines.
A 20% higher or lower mortality is substantial, and even under these assumptions the estimated age-sex annual incidence is contained
within the original 95% credible intervals, assuming nondifferential mortality between cases and non-cases of late AMD.
VOL. 160, NO. 1 93.e2AMERICAN WHITE INCIDENCE OF AGE-RELATED MACULAR DEGENERATION
SUPPLEMENTAL TABLE. Estimated Number of Prevalent Cases of Late Age-Related Macular Degeneration, Geographic Atrophy,
Neovascular Age-Related Macular Degeneration, and Average Prevalence by 5-Year Age Groups for Men and Women in the White
American Population
Age Group (Years)
Number of Prevalent Cases in 10 000s (95% Cri) Estimated Prevalence as % (95%Cri)
Late AMD GA NVAMD Late AMD GA NVAMD
Men
50–54 1.0 (0.6, 2.0) 0.6 (0.3, 1.1) 0.7 (0.4, 1.3) 0.1 (0.1, 0.2) 0.1 (0.0, 0.1) 0.1 (0.0, 0.1)
55–59 1.9 (1.0, 3.5) 1.1 (0.6, 1.9) 1.2 (0.7, 2.2) 0.2 (0.1, 0.4) 0.1 (0.1, 0.2) 0.2 (0.1, 0.3)
60–64 3.3 (1.8, 6.1) 1.9 (1.1, 3.2) 2.1 (1.2, 3.7) 0.5 (0.3, 0.9) 0.3 (0.2, 0.5) 0.3 (0.2, 0.5)
65–69 4.8 (2.6, 8.7) 2.7 (1.6, 4.5) 3.0 (1.7, 5.1) 0.9 (0.5, 1.7) 0.5 (0.3, 0.9) 0.6 (0.3, 1.0)
70–74 6.8 (3.8, 12.3) 3.8 (2.4, 6.3) 4.1 (2.4, 7.0) 1.9 (1.0, 3.4) 1.1 (0.7, 1.7) 1.1 (0.7, 1.9)
75–79 10.0 (5.6, 17.7) 5.7 (3.6, 9.1) 5.9 (3.6, 10.0) 3.7 (2.1, 6.6) 2.1 (1.3, 3.4) 2.2 (1.3, 3.7)
80–84 14.2 (8.1, 24.5) 8.1 (5.2, 13.0) 8.3 (5.0, 14.0) 7.2 (4.1, 12.4) 4.1 (2.6, 6.6) 4.2 (2.5, 7.1)
85–89 15.4 (9.0, 25.5) 9.1 (5.8, 14.5) 9.0 (5.5, 15.1) 13.3 (7.8, 21.9) 7.9 (5.0, 12.5) 7.8 (4.7, 13.0)
90þ 14.7 (9.1, 22.3) 9.2 (5.9, 14.3) 8.9 (5.5, 14.5) 25.2 (15.6, 38.3) 15.8 (10.1, 24.5) 15.3 (9.4, 24.8)
All ages 72.1 (41.4, 122.7) 42.2 (26.3, 67.9) 43.2 (26.0, 73.0) 1.8 (1.1, 3.1) 1.1 (0.7, 1.7) 1.1 (0.7, 1.9)
Women
50–54 1.1 (0.6, 2.0) 0.6 (0.3, 1.2) 0.7 (0.4, 1.3) 0.1 (0.1, 0.2) 0.1 (0.0, 0.1) 0.1 (0.0, 0.1)
55–59 2.0 (1.0, 3.7) 1.1 (0.6, 2.0) 1.3 (0.7, 2.3) 0.2 (0.1, 0.4) 0.1 (0.1, 0.2) 0.2 (0.1, 0.3)
60–64 3.5 (1.9, 6.5) 2.0 (1.1, 3.5) 2.3 (1.3, 4.0) 0.5 (0.3, 0.9) 0.3 (0.2, 0.5) 0.3 (0.2, 0.5)
65–69 5.3 (2.9, 9.8) 3.0 (1.8, 5.0) 3.3 (1.9, 5.7) 0.9 (0.5, 1.7) 0.5 (0.3, 0.9) 0.6 (0.3, 1.0)
70–74 8.1 (4.5, 14.7) 4.6 (2.8, 7.5) 4.9 (2.9, 8.4) 1.9 (1.0, 3.4) 1.1 (0.7, 1.7) 1.1 (0.7, 1.9)
75–79 13.2 (7.4, 23.4) 7.5 (4.7, 12.0) 7.8 (4.7, 13.2) 3.7 (2.1, 6.6) 2.1 (1.3, 3.4) 2.2 (1.3, 3.7)
80–84 21.8 (12.4, 37.7) 12.5 (7.9, 20.0) 12.7 (7.7, 21.5) 7.2 (4.1, 12.5) 4.2 (2.6, 6.6) 4.2 (2.6, 7.1)
85–89 29.4 (17.1, 48.4) 17.4 (11.0, 27.5) 17.2 (10.5, 28.8) 13.4 (7.8, 22.1) 7.9 (5.0, 12.6) 7.9 (4.8, 13.2)
90þ 37.0 (22.9, 55.9) 23.3 (14.9, 36.1) 22.5 (13.9, 36.4) 25.8 (16.0, 39.1) 16.3 (10.4, 25.2) 15.7 (9.7, 25.4)
All ages 121.3 (70.8, 202.1) 72.0 (45.2, 114.7) 72.7 (44.0, 121.6) 2.7 (1.6, 4.5) 1.6 (1.0, 2.5) 1.6 (1.0, 2.7)
Men and women
50–54 1.9 (1.3, 2.9) 1.0 (0.5, 1.7) 1.0 (0.6, 1.7) 0.1 (0.1, 0.2) 0.1 (0.0, 0.1) 0.1 (0.0, 0.1)
55–59 3.6 (2.4, 5.2) 1.8 (1.1, 2.9) 1.9 (1.2, 2.9) 0.2 (0.1, 0.3) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2)
60–64 6.5 (4.4, 9.3) 3.2 (2.0, 5.1) 3.3 (2.2, 4.9) 0.4 (0.3, 0.6) 0.2 (0.1, 0.3) 0.2 (0.2, 0.3)
65–69 9.7 (6.7, 13.8) 4.9 (3.2, 7.3) 4.9 (3.4, 7.0) 0.9 (0.6, 1.3) 0.5 (0.3, 0.7) 0.5 (0.3, 0.7)
70–74 14.7 (10.1, 20.6) 7.4 (5.0, 10.8) 7.4 (5.1, 10.1) 1.8 (1.3, 2.6) 0.9 (0.6, 1.4) 0.9 (0.6, 1.3)
75–79 23.2 (16.2, 32.2) 11.9 (8.2, 17.0) 11.5 (8.2, 15.7) 3.7 (2.6, 5.2) 1.9 (1.3, 2.7) 1.9 (1.3, 2.5)
80–84 36.6 (25.7, 50.3) 19.2 (13.2, 27.4) 18.3 (13.1, 24.9) 7.3 (5.2, 10.1) 3.9 (2.7, 5.5) 3.7 (2.6, 5.0)
85–89 46.3 (33.0, 62.4) 25.2 (17.3, 35.9) 23.6 (16.8, 32.2) 13.8 (9.9, 18.6) 7.5 (5.2, 10.7) 7.0 (5.0, 9.6)
90þ 54.0 (39.9, 69.6) 31.8 (21.8, 45.0) 29.4 (20.8, 40.1) 26.8 (19.8, 34.6) 15.8 (10.8, 22.3) 14.6 (10.3, 19.9)
All ages 196 (140, 266) 106 (72.4, 153) 101 (71.4, 139) 2.3 (1.7, 3.2) 1.3 (0.9, 1.8) 1.2 (0.8, 1.7)
95% Cri ¼ Bayesian 95% credible interval; AMD¼ age-related macular degeneration; GA ¼ geographic atrophy/dry AMD; NV ¼ neovascu-
lar/exudative/wet AMD.
Estimates for men and women combined are based on a meta-analysis of prevalence from 30 studies. Estimates for men and women sepa-
rately are based on a meta-analysis of 19 studies that reported AMD prevalence by sex.
Absolute number of prevalent cases is calculated by multiplying the numbers in the second column by 10 000 (eg, total number of cases
across all ages in men and women combined is 196 3 10 000 ¼ 1 960 000).
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